Novartis may face tough action over 'fake' documents in India
This article was originally published in Scrip
Executive Summary
Novartis could be headed for yet more challenging times in India marked by an erosion in its reputational capital, after it was pulled up by the Drugs Controller General of India (DCGI) for providing allegedly "fake documents" to re-register a veterinary product in the country.